Skip to main content

Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare

Shionogi, an Osaka innovative pharma, has signed an option agreement with Cilcare of France to in-license two drug candidates aimed at hearing loss in a deal worth up to $445 million. Meanwhile, XtalPi raised $126.8 million in a Hong Kong IPO.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.